A pairing appears on this page only when a trial gave both ingredients together and measured the result. Butyric acid has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Resistant starch reaches the colon undigested and is among the most butyrogenic substrates available to the resident flora. Rather than delivering butyrate, it lets the bacteria make it in place, along the length of the colon where oral doses struggle to reach. The size of the shift depends on which organisms a person already carries.
Inulin is fermented in the proximal colon, feeding bifidobacteria that release acetate and lactate. Butyrate-producing species then cross-feed on those intermediates. The route is indirect and the gas that comes with rapid proximal fermentation is the usual tolerance limit.
Shorter-chain fructans ferment faster and further up the colon than inulin, so they raise short-chain fatty acid output early in transit. Butyrate arises mostly through cross-feeding rather than direct production. Bloating tends to appear sooner with the shorter chains.
Galactooligosaccharides are selectively fermented by bifidobacteria, which do not themselves make butyrate but supply the acetate that butyrate producers consume. The pairing is a substrate-plus-consumer arrangement. Output depends on whether butyrogenic species are present to take up the acetate.
Partially hydrolysed guar gum ferments slowly and distally, so short-chain fatty acid release is spread across the colon instead of concentrated at the start. That profile is the reason it is chosen where rapid fructan fermentation is poorly tolerated. It is a substrate, not a source of butyrate itself.
Pectin is fermented to a mixture of acetate, propionate and butyrate, with the ratio shifting by pectin source and degree of esterification. It also raises viscosity in the small intestine, which slows delivery of everything else in the meal. Both effects travel together and cannot be separated by dose.
Oat beta-glucan is largely fermented rather than excreted, contributing to the colonic short-chain fatty acid pool. Molecular weight drives both viscosity and how quickly it is broken down, so processed and intact preparations behave differently. It is one substrate among several and not a substitute for a mixed fibre intake.
Psyllium is only partly fermented, which is precisely why it holds water and bulks stool rather than producing gas. Its contribution to butyrate output is smaller than that of fully fermentable fibres. Pairing it with a fermentable fibre gives bulk and substrate from different sources.
Bifidobacteria do not produce butyrate. They release acetate and lactate, which butyrate-forming species such as Faecalibacterium prausnitzii and Anaerostipes convert onward. That handoff is the reason a bifidobacterial strain can raise butyrate without making any.
Lactate from lactobacilli is a substrate for lactate-utilising butyrate producers in the colon. Whether that translates into more butyrate depends on whether those consumers are present; without them lactate simply accumulates. Read the pairing as conditional on an individual's existing flora.
This yeast does not make butyrate and is not fermented into it. Its relevance is that it alters the bacterial community during and after antibiotic courses, which is when butyrate producers are most depleted. The link to butyrate output is indirect and inconsistently measured.
Glutamine is the preferred fuel of small intestinal enterocytes while butyrate dominates colonocyte energy supply. The two feed different segments of the same tissue rather than competing. Pairing them covers more of the tract than either does alone, which is a rationale rather than a demonstrated outcome.
Activated charcoal is a broad, non-selective adsorbent and will bind organic acids and much else taken alongside it. Any oral butyrate given in the same window is liable to be adsorbed before it is absorbed. Separating the two by several hours is the practical answer.
Clay adsorbents bind small charged molecules in the gut lumen without discriminating between what is wanted and what is not. Taken together with a butyrate salt, the exposure that reaches the mucosa is reduced by an amount nobody has quantified. Spacing the doses removes the question.
Both are used with an eye on the gut lining, but their evidence bases sit in different compartments and different segments of the tract. No study has run them together. The pairing is a formulation choice at present, not a tested combination.
Butyrate is usually supplied as a calcium, magnesium or sodium salt because the free acid smells of rancid butter. That means a butyrate dose also carries a mineral dose, which counts against the day's total. The mineral is a consequence of the delivery choice rather than an intended active.
Nothing specific on file for Butyric acid. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 9 we read for Butyric acid. The full linked list is below.
3 sources behind our Butyric acid verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Read this carefully. These are 161 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Butyric acid is, not how risky it is. A report is not proof Butyric acid caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.